Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
First Claim
Patent Images
1. A method of enhancing the bioavailability of dextromethorphan comprising co-administering to a human being twice a day for at least 14 consecutive days a combination of:
- a. a bupropion, a hydroxybupropion, a threohydroxybupropion, or an erythrohydroxybupropion;
withb. a dextromethorphan;
wherein co-administration of the bupropion, the hydroxybupropion, the threohydroxybupropion, or the erythrohydroxybupropion, with the dextromethorphan results in an onset of action for the dextromethorphan within two weeks from the first administration of the combination;
wherein the human being is an extensive metabolizer of the dextromethorphan in need of treatment with dextromethorphan;
wherein the bupropion, the hydroxybupropion, the erythrohydroxybupropion, or the threohydroxybupropion is administered in an amount that results in a Cmin of the dextromethorphan in the human being, on the eighth day, that is at least about 20 ng/mL and is at least 20 times the Cmin that would have been achieved by administering the same amount of the dextromethorphan without the bupropion, the hydroxybupropion, the erythrohydroxybupropion, or the threohydroxybupropion for 8 consecutive days, and wherein the dextromethorphan is present in the body of the human being at the same time as the bupropion, the hydroxybupropion, the erythrohydroxybupropion, or the threohydroxybupropion.
1 Assignment
0 Petitions
Accused Products
Abstract
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
224 Citations
29 Claims
-
1. A method of enhancing the bioavailability of dextromethorphan comprising co-administering to a human being twice a day for at least 14 consecutive days a combination of:
-
a. a bupropion, a hydroxybupropion, a threohydroxybupropion, or an erythrohydroxybupropion;
withb. a dextromethorphan; wherein co-administration of the bupropion, the hydroxybupropion, the threohydroxybupropion, or the erythrohydroxybupropion, with the dextromethorphan results in an onset of action for the dextromethorphan within two weeks from the first administration of the combination; wherein the human being is an extensive metabolizer of the dextromethorphan in need of treatment with dextromethorphan; wherein the bupropion, the hydroxybupropion, the erythrohydroxybupropion, or the threohydroxybupropion is administered in an amount that results in a Cmin of the dextromethorphan in the human being, on the eighth day, that is at least about 20 ng/mL and is at least 20 times the Cmin that would have been achieved by administering the same amount of the dextromethorphan without the bupropion, the hydroxybupropion, the erythrohydroxybupropion, or the threohydroxybupropion for 8 consecutive days, and wherein the dextromethorphan is present in the body of the human being at the same time as the bupropion, the hydroxybupropion, the erythrohydroxybupropion, or the threohydroxybupropion. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)
-
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeAntecip Bioventures II LLC
-
Original AssigneeAntecip Bioventures II LLC
-
InventorsTabuteau, Herriot
-
Primary Examiner(s)Baek, Bong-Sook
-
Application NumberUS15/236,290Publication NumberTime in Patent Office403 DaysField of SearchNoneUS Class CurrentCPC Class CodesA61K 2300/00 Mixtures or combinations of...A61K 31/137 Arylalkylamines, e.g. amphe...A61K 31/138 Aryloxyalkylamines, e.g. pr...A61K 31/485 Morphinan derivatives, e.g....A61K 9/0053 Mouth and digestive tract, ...A61P 25/24 Antidepressants
